Published in AIDS Weekly, November 11th, 2002
Designed for the treatment of HIV-1 in combination with other antiretroviral agents, Fuzeon is the most clinically advanced in an investigational class of anti-HIV drugs called "fusion inhibitors."
The priority review designation establishes a target 6-month review period for the Fuzeon NDA, which was submitted by Roche and Trimeris on September 16, 2002. The FDA will, therefore, take...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.